Literature DB >> 7694593

New strategies for enhancing the immunogenicity of tumors.

D M Pardoll1.   

Abstract

When a cancer grows in an individual, the immune system has either failed to recognize its antigens or failed to effectively respond. Increasing evidence for the existence of tumor antigens that are recognized by T cells provides a direct rationale for the design of novel strategies to either enhance tumor immunogenicity by genetic modification or utilize recombinant or peptide vaccines in cases where the relevant tumor antigens have been specifically identified.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7694593     DOI： 10.1016/0952-7915(93)90127-e

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  10 in total

Review 1.  New therapeutic approaches based on gene transfer techniques.

Authors:  H Chong; R G Vile
Journal:  Springer Semin Immunopathol       Date:  1996

Review 2.  T-cell antigens in cancer.

Authors:  T J Tsomides; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

3.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Authors:  J L Schultze; A A Cardoso; G J Freeman; M J Seamon; J Daley; G S Pinkus; J G Gribben; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

4.  Identification of the neoplastically transformed cells in Marek's disease herpesvirus-induced lymphomas: recognition by the monoclonal antibody AV37.

Authors:  Shane C Burgess; T Fred Davison
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

5.  In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma.

Authors:  S W Dow; R E Elmslie; A P Willson; L Roche; C Gorman; T A Potter
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

6.  A multipurpose brachytherapy catheter to enable intratumoral injection.

Authors:  Justin C Jagodinsky; Gabriella Medeiros; Hayley H Raj; Amira Razuan; Alexis Locsin; Tirhas G Dempsey; Beixiao Tang; Ishan Chakravarty; Paul A Clark; Raghava N Sriramaneni; Won Jong Jin; Keng-Hsueh Lan; Rupak K Das; Jessica R Miller; Darilis Suarez-Gonzalez; Zachary S Morris
Journal:  Brachytherapy       Date:  2021-03-27       Impact factor: 2.441

7.  Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.

Authors:  Stefanie Loeser; Karin Loser; Martijn S Bijker; Manu Rangachari; Sjoerd H van der Burg; Teiji Wada; Stefan Beissert; Cornelis J M Melief; Josef M Penninger
Journal:  J Exp Med       Date:  2007-04-02       Impact factor: 14.307

8.  Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.

Authors:  Eonju Oh; Il-Kyu Choi; JinWoo Hong; Chae-Ok Yun
Journal:  Oncotarget       Date:  2017-01-17

9.  Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.

Authors:  S Baskar; L Glimcher; N Nabavi; R T Jones; S Ostrand-Rosenberg
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

10.  Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.

Authors:  A Krause; H F Guo; J B Latouche; C Tan; N K Cheung; M Sadelain
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.